ATMI (ATMI) 10-Q 23 Oct 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Sep-13
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Entity Registrant Name	ATMI INC
Entity Central Index Key	1041577
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	31,841,502

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Assets
Cash and cash equivalents	$61,756	$86,050
Marketable securities, current portion	69,935	70,397
Accounts receivable, net of allowances of $781 and $881, respectively	58,691	60,806
Inventories, net	97,925	87,555
Deferred income taxes	7,970	4,488
Prepaid expenses	10,301	12,199
Other current assets	12,095	9,049
Total current assets	318,673	330,544
Property, plant, and equipment, net	141,763	125,099
Goodwill	47,162	46,830
Other intangibles, net	43,214	46,930
Marketable securities, non-current	6,609	12,073
Deferred income taxes, non-current	6,518	15,065
Other non-current assets	27,913	22,612
Total assets	591,852	599,153
Liabilities and stockholders’ equity
Accounts payable	33,206	38,573
Accrued liabilities	8,000	7,997
Accrued salaries and related benefits	7,768	5,992
Income taxes payable	3,215	16,256
Other current liabilities	4,125	6,084
Total current liabilities	56,314	74,902
Deferred income taxes, non-current	458	165
Other non-current liabilities	14,907	16,810
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, par value $.01 per share: 2,000 shares authorized; none issued	0	0
Common stock, par value $.01 per share: 100,000 shares authorized; 40,958 and 40,476 issued and 31,842 and 31,983 outstanding in 2013 and 2012, respectively	409	405
Additional paid-in capital	466,794	457,669
Treasury stock at cost (9,116 and 8,493 shares in 2013 and 2012, respectively)	-251,509	-237,170
Retained earnings	297,065	270,744
Accumulated other comprehensive income	7,414	15,628
Total stockholders’ equity	520,173	507,276
Total liabilities and stockholders’ equity	$591,852	$599,153

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$781	$881
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	40,958,000	40,476,000
Common stock, shares outstanding	31,842,000	31,983,000
Treasury stock, shares	9,116,000	8,493,000

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended				9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Income Statement [Abstract]
Revenues	$100,232	[1]	$108,847	[1]	$301,647	[1]	$307,320	[1]
Cost of revenues	53,978		54,404		160,049		155,221
Gross profit	46,254		54,443		141,598		152,099
Operating expenses:
Research and development	12,771		12,272		39,083		40,586
Selling, general and administrative	22,436		21,708		68,416		67,967
Total operating expenses	35,207		33,980		107,499		108,553
Operating income	11,047		20,463		34,099		43,546
Interest income	240		293		896		923
Other income, net	218		254		1,838		-509
Income before income taxes	11,505		21,010		36,833		43,960
Provision for income taxes	3,057		6,585		10,512		14,250
Net income	8,448		14,425		26,321		29,710
Earnings per common share — basic (in dollars per share)	$0.27		$0.45		$0.82		$0.93
Weighted average shares outstanding — basic (in shares)	31,861		31,964		31,937		31,904
Earnings per common share — diluted (in dollars per share)	$0.26		$0.44		$0.80		$0.91
Weighted average shares outstanding — diluted (in shares)	32,750		32,609		32,727		32,659
Comprehensive income	$10,352		$15,099		$18,107		$28,419
[1]	ntersegment sales for the three and nine month periods ended September 30, 2013 and 2012 were not material.

Consolidated_Statement_Of_Stoc

Consolidated Statement Of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]
In Thousands, unless otherwise specified
Beginning Balance at Dec. 31, 2012	$507,276	$405	$457,669	($237,170)	$270,744	$15,628
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of 207 shares of common stock pursuant to the exercise of employee stock options	3,505	2	3,503
Purchase of 624 treasury shares	-14,339			-14,339
Stock based compensation	5,624		5,624
Other		2	-2
Net income	26,321				26,321
Other Comprehensive loss	-8,214					-8,214
Total Comprehensive income	18,107
Ending Balance at Sep. 30, 2013	$520,173	$409	$466,794	($251,509)	$297,065	$7,414

Consolidated_Statement_Of_Stoc1

Consolidated Statement Of Stockholders' Equity (Parenthetical)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Statement of Stockholders' Equity [Abstract]
Issuance of common stock shares pursuant to the exercise of employee stock options, shares	207
Purchase of treasury shares	624

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating activities
Net income	$26,321	$29,710
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	21,661	20,203
Stock-based compensation expense	5,624	6,605
Deferred income taxes	9,762	464
Nonmonetary Transaction, Gross Operating Revenue Recognized	0	-2,600
Other	-290	3,019
Changes in operating assets and liabilities:
Accounts receivable	1,833	-15,291
Inventories	-11,815	-11,047
Other assets	6,965	4,125
Accounts payable	-5,321	4,433
Accrued expenses, income taxes and other liabilities	-15,501	12,648
Net cash provided by operating activities	39,239	52,269
Investing activities
Capital expenditures	-34,746	-18,420
Purchases of marketable securities	-97,899	-65,462
Proceeds from sales or maturities of marketable securities	92,739	81,081
Acquisitions of assets and investments	-12,230	-3,250
Other	50	117
Net cash used for investing activities	-52,086	-5,934
Financing activities
Purchases of treasury stock	-14,339	-1,562
Proceeds from exercise of stock options	3,505	1,157
Other	433	-29
Net cash used for financing activities	-10,401	-434
Effects of exchange rate changes on cash and cash equivalents	-1,046	39
Net (decrease) increase in cash and cash equivalents	-24,294	45,940
Cash and cash equivalents, beginning of period	86,050	34,523
Cash and cash equivalents, end of period	$61,756	$80,463

Description_Of_Business

Description Of Business	9 Months Ended
	Sep. 30, 2013
Description Of Business [Abstract]
Description of Business	Description of Business
	ATMI, Inc. (together with its subsidiaries, collectively referred to as the “Company,” “ATMI,” “our” or “we”), a global technology company, is a leading supplier of high performance materials, materials packaging and materials delivery systems used worldwide in various industries including microelectronics and life sciences. Our Microelectronics segment products consist of “front-end” semiconductor performance materials, sub-atmospheric pressure gas delivery systems for safe handling and delivery of toxic and hazardous gases to semiconductor process equipment, and high-purity materials packaging and dispensing systems that allow for the reliable introduction of low volatility liquids to microelectronics processes. ATMI targets semiconductor and flat-panel display manufacturers, whose products form the foundation of microelectronics technology rapidly proliferating through the consumer products, information technology, automotive, and communications industries. The market for microelectronics devices is continually changing, which drives demand for new products and technologies that have improved performance at lower cost. Our customers include the leading semiconductor manufacturers in the world who target leading-edge technologies. In our LifeSciences segment, we address an increasing number of single-use development and manufacturing needs for the life sciences markets. Our proprietary containment, mixing, and bioreactor technologies are sold to biotechnology, cell therapy and pharmaceutical companies involved in the manufacture of vaccine, monoclonal antibodies and cell therapy applications, which we believe offer significant long-term growth potential. ATMI’s objective is to meet the demands of our microelectronics and life sciences customers with solutions that maximize the efficiency and safety of their manufacturing processes, reduce capital or operating costs, and minimize the time to develop new products and integrate them into their processes.

Basis_Of_Presentation_And_Othe

Basis Of Presentation And Other Information	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Other Information	Basis of Presentation and Other Information
	Basis of Presentation
	The accompanying consolidated interim financial statements of ATMI, Inc. at September 30, 2013 and for the three and nine months ended September 30, 2013 and 2012, respectively, are unaudited, but in the opinion of management include all adjustments necessary for a fair presentation of the results for the interim periods. The unaudited consolidated interim financial statements included herein should be read in conjunction with the December 31, 2012 audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. The Company’s quarterly results are subject to fluctuation and, thus, the operating results for any quarter are not necessarily indicative of results to be expected for any future fiscal period.
	The consolidated balance sheet at December 31, 2012 has been derived from the audited financial statements at that date, but does not include all of the financial information and disclosures required by United States Generally Accepted Accounting Principles (“GAAP”) for complete financial statements.
	Earnings Per Share
	This table shows the computation of basic and diluted earnings per share (in thousands, except per share data):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2013				2012			2013		2012
	Numerator:
	Net income	$	8,448			$	14,425		26,321		29,710
	Denominator:
	Denominator for basic earnings per share - weighted average shares	31,861				31,964			31,937		31,904
	Dilutive effect of employee stock options	162				145			143		178
	Dilutive effect of restricted stock awards and restricted stock units	727				500			647		577
	Denominator for diluted earnings per common share – weighted average shares	32,750				32,609			32,727		32,659
	Earnings per share-basic	$	0.27			$	0.45		$	0.82	$	0.93
	Earnings per share-diluted	$	0.26			$	0.44		$	0.8	$	0.91
	This table shows the potential common shares excluded from the calculation of weighted-average shares outstanding because their effect was considered to be antidilutive (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	Antidilutive shares	573			1,085			861		1,117
	Inventories
	Inventories include (in thousands):
		September 30,				December 31,
		2013				2012
	Raw materials	$	30,565			$	26,874
	Work in process	3,305				2,064
	Finished goods	68,023				62,003
		101,893				90,941
	Excess and obsolescence reserve	(3,968		)		(3,386		)
	Inventories, net	$	97,925			$	87,555
	Non-marketable Equity Securities
	We selectively invest in non-marketable equity securities of private companies, which range from early-stage companies to more mature companies whose products or technologies may directly support an ATMI product or initiative. At September 30, 2013, the carrying value of our portfolio of strategic investments in non-marketable equity securities totaled $16.4 million ($8.1 million at December 31, 2012), of which $7.1 million are accounted for at cost ($5.4 million at December 31, 2012), and $9.3 million are accounted for using the equity method of accounting ($2.7 million at December 31, 2012). Non-marketable equity securities are included in the consolidated balance sheets under the caption “Other non-current assets.” ATMI’s share of the income or losses of all equity-method investees, using the most current financial information available, which is one month behind ATMI’s normal closing date, is included in our results of operations from the investment date forward.
	Income Taxes
	We have not provided for U.S. federal income and foreign withholding taxes on approximately $100.4 million of undistributed earnings from non-U.S. operations as of September 30, 2013, because such earnings are intended to be reinvested indefinitely outside of the United States. These earnings could become subject to additional tax if they are remitted as dividends, loaned to ATMI, or upon sale of subsidiary stock. It is not practicable to estimate the amount or timing of the additional tax, if any, that eventually might be paid on the foreign earnings.
	We had an effective income tax rate of 26.6 percent and 28.5 percent for the three and nine month periods ended September 30, 2013. The effective income tax rate differs from the U.S. federal statutory income tax rate of 35.0 percent primarily due to the mix of income attributable to the various countries in which we conduct business, the increase in the valuation allowance on certain foreign losses, and the impact of our reserves. The year-to-date effective income tax rate includes a $1.2 million settlement with the South Korea taxing authority, $1.1 million of benefits for certain 2012 retroactive provisions of The American Taxpayer Relief Act of 2012 (signed into law on January 2, 2013) including the US R&D credit, $2.2 million net benefit for reversals of previously established reserves, and a $0.2 million provision related to equity-based compensation. The effective income tax rate is calculated based on full-year assumptions and is affected by the mix of income attributable to the various countries in which we conduct business. We continue to incur losses at Artelis, our iCELLis® and Xpansion™ bioreactor business, and as a result, we have not recorded a tax benefit on these losses. If a tax benefit had been reflected on the foreign losses, our effective income tax rate would have been approximately 25.6 percent and 24.5 percent for the three and nine month periods ended September 30, 2013, respectively.
	At September 30, 2013, the Company had $2.6 million of unrecognized tax benefits, which if recognized, would favorably affect the effective income tax rate in future periods. $0.2 million of this amount is included in deferred taxes, $0.2 million is included in the caption “Other current liabilities,” and the balance of $2.2 million is included in the caption “Other non-current liabilities” on the consolidated balance sheets. In addition, the Company has $0.5 million of total accrued interest (net) on tax reserves. In the next 12 months, the Company does not expect any material decreases to the unrecognized tax benefits for tax positions taken related to previously filed tax returns.
	At December 31, 2012, the Company had $27.0 million of unrecognized tax benefits related to the timing of deduction of the reacquired rights due to the Matheson contract termination. This uncertainty was resolved in the period ended June 30, 2013 as the Internal Revenue Service completed the audit of tax years 2010 and 2011, for which the Company paid $8.2 million (including $0.2 million of interest) in October 2013. Except for interest expense associated with the timing of the payment, since it was an uncertainty related to the timing of the deduction, the reversal of the $27.0 million of unrecognized tax benefits in 2013 had no impact on the income statement or on our effective tax rate.   The reversal also resulted in a reclassification between taxes payable and deferred taxes on the balance sheet, to properly reflect in deferred tax assets the future amortization tax effect of the reacquired rights.
	In the second quarter of 2013, the Company reached a settlement with the South Korea tax authority to settle income tax issues related to tax years 2008-2012 for a payment of approximately $1.2 million (including interest and penalties).
	Variable Interest Entity
	We hold a variable interest in the equity of Anji Microelectronics Co., Ltd. (“Anji”), an entity that produces advanced semiconductor materials, with primary operations in Shanghai, China. We have determined that we are not the primary beneficiary of Anji because we do not have the power, through voting or similar rights, to direct the activities of Anji that most significantly impact the entity’s economic performance, and we are also not expected to absorb significant losses or gains from Anji. ATMI’s carrying value of this cost basis investment is $3.9 million at September 30, 2013. The carrying value of our investment in Anji represents the cash paid, less our share of the cumulative losses during the period that we used the equity-method of accounting. At September 30, 2013, our maximum exposure to loss is our carrying value in this investment of $3.9 million.
	Severance Expense
	During the first quarter of 2013, we initiated an action in our Microelectronics business to better streamline business activities with our customers and partners. As a result, we recognized $1.8 million of severance expense under the caption, Selling, general & administrative in the consolidated statements of comprehensive income. During the first nine months of 2013, we paid $1.7 million associated with this action. We do not anticipate any material additional charges associated with this action. Because the actions were driven by ATMI’s executive team, and are not considered by management to be part of segment results as they were not driven by the Microelectronics segment manager, the severance charge is reflected in the All Other segment.
	As part of our operating margin improvement objectives, during the third quarter of 2013, we executed an action in our Microelectronics business to reduce operational infrastructure with the objective of streamlining operations. As a result, we recognized $0.8 million of severance expense under the caption, Selling, general & administrative in the consolidated statements of comprehensive income. We did not make any payments related to this action during the third quarter of 2013. We do not anticipate any material additional charges associated with this action. Because the actions were driven by ATMI’s executive team, and are not considered by management to be part of segment results as they were not driven by the Microelectronics segment manager, the severance charge is reflected in the All Other segment.
	Recently Adopted Accounting Pronouncements
	In December 2011, the FASB issued ASU 2011-11-”Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities” and in January 2013, the FASB issued ASU 2013-01- “Balance Sheet (Topic 210): Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities.” In ASU 2011-11, entities are required to disclose both gross information and net information about both instruments and transactions eligible for offset in the statement of financial position and instruments and transactions subject to an agreement similar to a master netting arrangement. ASU 2013-01 limits the scope of disclosures to derivatives, repurchase agreements and securities lending arrangements. We were required to apply the amendments retrospectively for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. There was no material impact from the adoption of these Updates.
	In February 2013, the FASB issued ASU 2013-02-”Comprehensive Income (Topic 220): Reporting of Amounts Reclassified out of Accumulated Other Comprehensive Income.” Substantially all of the information that this Update requires was already disclosed in our financial statements under U.S. GAAP, however, this Update requires additional disclosure about amounts reclassified out of accumulated other comprehensive income and their corresponding effect on net income in one place. We were required to apply the amendments prospectively for annual reporting periods beginning after December 15, 2012. There was no material impact from the adoption of this Update. See Note 5 for the disclosures as a result of adoption of this Update.
	Recently Issued Accounting Pronouncements
	In July 2013, the FASB issued ASU 2013-11-“Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” In this update, entities are required to offset a liability related to an unrecognized tax benefit against a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. An entity is required to apply the amendments prospectively for annual reporting periods beginning after December 15, 2013, and interim periods within those annual periods. Retrospective application is permitted. We do not anticipate any material impact from this Update.

EquityBased_Compensation

Equity-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity-Based Compensation	Equity-Based Compensation
	Summary of Plans
	This table shows the number of shares approved by stockholders for each plan and the number of shares that remain available for equity awards at September 30, 2013 (in thousands):
		# of Shares	# of Shares
	Stock Plan	Approved	Available
	2010 Stock Plan (1)	3,000	2,206
	Employee Stock Purchase Plan (2)	1,000	230
	Totals	4,000	2,436
	(1)	Exercise prices for ISOs and non-qualified stock options granted under this plan may not be less than 100 percent of the fair market value for the Company’s common stock on the date of grant.
	(2)	Employees may purchase shares at 95 percent of the closing price on the day previous to the last day of each six-month offering period. This plan is not considered to be compensatory.
	The Company issued 207,288 shares of common stock as a result of exercises by employees under its employee stock option plans during the first nine months of 2013. Such amount was 258,446 shares of common stock during the fiscal year ended December 31, 2012. The Company issued 324,315 shares of restricted stock awards that include solely a time-based vesting requirement in the first nine months of 2013 and such amount was 321,965 during the fiscal year ended December 31, 2012.

Fair_Value_Measurements_And_Ma

Fair Value Measurements And Marketable Securities	9 Months Ended
	Sep. 30, 2013
Investments, All Other Investments [Abstract]
Fair Value Measurements and Marketable Securities	Fair Value Measurements and Marketable Securities
	The Company measures and reports financial assets and financial liabilities on a fair value basis, consistent with ASC 820 “Fair Value Measurements and Disclosures,” using the following three categories for classification and disclosure purposes:
	Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 1 assets and liabilities consist of cash, money market fund deposits, time deposits, certain of our marketable equity instruments, and forward foreign currency exchange contracts that are traded in an active market with sufficient volume and frequency of transactions.
	Level 2 — Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets include certain of our marketable debt instruments with quoted market prices that are traded in less active markets or priced using a quoted market price for similar instruments.
	Level 3 — Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. At September 30, 2013, the Artelis acquisition contingent consideration payment liability, which is categorized as a non-recurring fair value measurement, is the only item valued in this category.
	Assets / Liabilities Measured at Fair Value on a Recurring Basis
	This table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis at September 30, 2013 (in thousands):
				Fair Value Measured Using
		Total		Quoted			Significant		Significant
				Prices in			Other		Unobservable
				Active			Observable		Inputs
				Markets for			Inputs		(Level 3)
				Identical			(Level 2)
				Assets
				(Level 1)
	Cash & cash equivalents	$	61,756	61,756
	Available-for-sale marketable securities
	Common stock	$	18,841	$	18,841
	Time deposits	$	22,337	$	22,337
	Corporate debt obligations	$	7,257				$	7,257
	Government debt obligations	$	24,380				$	24,380
	Government sponsored debt obligations	$	3,729				$	3,729
	Foreign currency exchange contract asset	$	1	$	1
	Foreign currency exchange contract liability	$	22	$	22
	During the first nine months of 2013, our valuation methodologies were consistent with previous years, and there were no transfers made among the three levels of the valuation hierarchy.
	Assets / Liabilities Measured at Fair Value on a Nonrecurring Basis
	All assets and liabilities measured at fair value on a nonrecurring basis are categorized as Level 3, requiring significant management judgment due to the absence of quoted market prices or observable inputs for assets of a similar nature.
	Consistent with prior quarters, the liability for the Artelis contingent consideration payments, which is classified as Level 3, and is tied to future revenue performance for the fiscal years 2013 through 2014, was calculated using unobservable inputs (primarily using discounted cash flow analysis, a current average discount rate of 5.5 percent, and reliance on the market and product knowledge of internal experts). The contingent payments have a range of possible outcomes from $0 to $23.3 million, subject to movements in currency.
	Our estimate of the fair value of the Artelis contingent payments was $4.9 million at September 30, 2013, representing an increase in our estimated payments of $0.3 million from December 31, 2012. This increase was driven by foreign currency translation and an increase in our assessment of our future payment obligation due to an increase in our assessment of anticipated future revenues.
	Due to their nature, the carrying value of cash, receivables, and payables approximates fair value.
	Marketable securities include at September 30, 2013 and December 31, 2012 (in thousands):
		2013							2012
		Cost		Gross			Estimated		Cost			Gross			Estimated
				Unrealized			Fair Value					Unrealized			Fair Value
				Gain (Loss) (3)								Gain (Loss) (3)
	Securities in unrealized gain position:
	Common stock	$	251	$	1,131		$	1,382	$	22,376		$	13,049		$	35,425
	Corporate debt obligations	3,429		6			3,435		4,211			4			4,215
	Government debt obligations (1)	21,489		11			21,500		4,495			14			4,509
	GSE (2) debt obligations	—		—			—		3,501			—			3,501
	U.S. Treasury obligations	—		—			—		4,023			—			4,023
	Subtotal	25,169		1,148			26,317		38,606			13,067			51,673
	Securities in unrealized loss position:
	Common stock	18,748		(1,289		)	17,459		—			—			—
	Corporate debt obligations	3,825		(3		)	3,822		4,844			(7		)	4,837
	Government debt obligations	2,882		(2		)	2,880		—			—			—
	GSE debt obligations	3,730		(1		)	3,729		—			—			—
	U.S. Treasury obligations	—		—			—		8,251			(1		)	8,250
	Subtotal	29,185		(1,295		)	27,890		13,095			(8		)	13,087
	Securities at amortized cost:
	Time deposits	22,337		—			22,337		16,920			—			16,920
	Corporate debt obligations	—		—			—		790			—			790
	Subtotal	22,337		—			22,337		17,710			—			17,710
	Total marketable securities	$	76,691	$	(147	)	$	76,544	$	69,411		$	13,059		$	82,470
	(1)	State and municipal government debt obligations.
	(2)	Government sponsored enterprise.
	(3)	Unrealized gains or losses of less than $500 for each category are reflected as a dash.
	The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity, as of September 30, 2013 are shown below (in thousands); expected maturities may differ from contractual maturities because the issuers of the securities may exercise the right to prepay obligations without prepayment penalties.
		Cost		Estimated
				Fair Value
	Due in one year or less	$	49,700	$	49,709
	Due between one and three years	7,992		7,994
		57,692		57,703
	Common stock	18,999		18,841
	$	76,691	$	76,544
This table shows the Company’s marketable securities that were in an unrealized loss position at September 30, 2013, and also shows the period of time the security had been in an unrealized loss position (in thousands):
	Less Than 12 Months					12 Months or Greater					Total
	Fair Value		Unrealized			Fair Value		Unrealized			Fair Value			Unrealized
			Losses					Losses						Losses
Common stock	$	17,459	$	(1,289	)	$	—	$	—		$	17,459		$	(1,289	)
Corporate debt obligations	$	—	$	—		$	3,822	$	(3	)	$	3,822		$	(3	)
Government debt obligations	2,880		(2		)	—		—			2,880			(2		)
GSE (1) debt obligations	3,729		(1		)	—		—			3,729			(1		)
Total (2)	$	24,068	$	(1,292	)	$	3,822	$	(3	)	$	27,890		$	(1,295	)
(1)	Government sponsored enterprise.
(2)	As of September 30, 2013, we had 10 securities in an unrealized loss position. We have evaluated the near-term prospects of the investments in relation to the severity and duration of the decline in fair value and based on that evaluation we have concluded that we have the ability and intent to hold these investments until the recovery of fair value.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income
	The components of accumulated other comprehensive income are (in thousands):
		Currency			Unrealized			Unrealized			Total
		Translation			Gain (Loss)			Gain (Loss)
		Adjustments			on Available-			on Derivative
					for-Sale			Instruments
					Securities
	Balance at December 31, 2012	$	6,300		$	8,230		$	1,098		$	15,628
	Reclassification adjustment related to marketable securities in net unrealized gain at prior period end, net of $1,140 tax provision (1)	—			(2,002		)	—			(2,002		)
	Change in fair value of available-for-sale securities, net of deferred income tax of $3,650	—			(6,338		)	—			(6,338		)
	Reclassification adjustment related to cash flow hedges at prior period end in a net unrealized loss at prior period end, net of deferred income tax of $334	—			—			(585		)	(585		)
	Change in fair value of cash flow hedges, net of deferred income tax of $511	—			—			896			896
	Cumulative translation adjustment	(185		)	—			—			(185		)
											(8,214		)
	Balance at September 30, 2013	$	6,115		$	(110	)	$	1,409		$	7,414
	(1)	Determined based on the average cost method
	The reclassifications out of accumulated other comprehensive income are (in thousands):
	Details about Accumulated Other Comprehensive	Amount Reclassified from			Effect on the Consolidated
	Income Components	Accumulated Other			Statements of Comprehensive Income
		Comprehensive Income
	Realized gains and losses on cash flow hedges
	Foreign exchange contracts	$	1,057		Revenues
		(138		)	Cost of revenues
		919			Total before tax
		(334		)	Estimated tax expense
		$	585		Net of estimated tax
	Realized gains and losses on available-for-sale securities
	Available-for-sale securities	$	3,142		Other income (expense), net
		3,142			Total before tax
		(1,140		)	Estimated tax expense
		$	2,002		Net of estimated tax
	Total reclassifications for the period	$	2,587		Net of estimated tax

Foreign_Currency_Exchange_Cont

Foreign Currency Exchange Contracts	9 Months Ended
	Sep. 30, 2013
Foreign Currency Derivatives [Abstract]
Foreign Currency Exchange Contracts	Foreign Currency Exchange Contracts
	We use forward foreign currency exchange contracts to hedge specific or anticipated exposures relating to intercompany payments (primarily U.S. export sales to subsidiaries at pre-established U.S. dollar prices), intercompany loans, future cash flows and other specific and identified exposures. The terms of the forward foreign currency exchange contracts are matched to the underlying transaction being hedged. Because such contracts are directly associated with identified transactions, they are an effective hedge against fluctuations in the value of the foreign currency underlying the transaction.
	Changes in the fair value of economic hedges are recognized in earnings as an offset to the change in the fair value of the underlying exposures being hedged. The changes in fair value of derivatives that are designated as cash-flow hedges are deferred in accumulated other comprehensive income (loss) and are recognized in earnings when the underlying hedged transaction occurs. Any ineffectiveness is recognized in earnings immediately. Gains and losses on hedges are reported as a net change in cash provided or used by operating activities. We do not enter into derivative instruments for trading or speculative purposes and all of our derivatives were effective throughout the periods reported.
	Counterparties to forward foreign currency exchange contracts are major banking institutions with credit ratings of investment grade or better and no collateral is required. There are no significant risk concentrations. We believe the risk of incurring losses on derivative contracts related to credit risk is remote.
	At September 30, 2013, we held foreign currency exchange contracts, not designated as cash flow hedges, with notional amounts totaling $21.2 million of which $8.3 million will be settled in Euros, $1.4 million will be settled in Taiwan Dollars, $1.2 million will be settled in Chinese Yuan Renminbi, and $10.3 million will be settled in Japanese Yen. At September 30, 2013, we held forward foreign currency exchange contracts designated as cash flow hedges with notional amounts totaling $15.6 million, which will be settled in Japanese Yen. The cash flow hedges held at September 30, 2013 mature between the fourth quarter of 2013 and the fourth quarter 2014. At September 30, 2013, the accumulated net unrecognized gains that are expected to be reclassified into earnings during the next twelve months are $1.3 million.
	The Company recorded net losses of $0.5 million and $0.1 million for the three and nine months ended September 30, 2013, and a net loss of $0.1 million and net gain of $0.6 million for the three and nine months ended September 30, 2012, respectively, under the caption "Other income (expense), net" in the consolidated statements of comprehensive income related to changes in the fair value of the foreign currency exchange contract economic hedges. The Company recorded a net loss of $0.6 million and a net gain of $0.3 million for the three and nine months ended September 30, 2013 in other comprehensive income related to the change in the fair value of cash flow hedges. The Company recorded a net loss of $0.2 million for the three and nine months ended September 30, 2012 in other comprehensive income related to the change in the fair value of cash flow hedges.

Commitments_And_Contingencies

Commitments And Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	ATMI is, from time to time, involved in legal actions, governmental audits, and proceedings relating to various matters incidental to its business including contract disputes, intellectual property disputes, product liability claims, employment matters, export and trade matters, and environmental claims. While the outcome of such matters cannot be predicted with certainty, in the opinion of management, after reviewing such matters and consulting with ATMI’s counsel and considering any applicable insurance or indemnifications, any liability which may ultimately be incurred is not expected to materially affect ATMI’s consolidated financial position, cash flows or results of operations.
	As part of the Artelis acquisition, we recognized a liability for the fair value of contingent payments tied to anticipated future revenue performance, which is currently valued at $4.9 million. The range of possible outcomes related to the contingent payment obligation is $0 to $23.3 million, subject to movements in currency. See Note 4 for further discussion.
	In the first quarter of 2013, we executed a $16.0 million commitment to purchase raw material from a strategic gas supplier over the next two years. We have purchased approximately $7.0 million in raw materials through the nine months ended September 30, 2013 and now have remaining commitments under this agreement of approximately $9.0 million.

Segments

Segments	9 Months Ended
	Sep. 30, 2013
Segment Reporting, Measurement Disclosures [Abstract]
Segments	Segments
	ATMI has two reportable operating segments, Microelectronics and LifeSciences. Our Chief Executive Officer regularly reviews financial information which separately identifies each segment’s results.
	The Microelectronics business unit sells high-purity materials and materials delivery systems for integrated circuit and flat-panel display manufacturing. Microelectronics products consist of ATMI’s patented Safe Delivery Source® (“SDS”) solutions to deliver ion implant gases, copper materials for plating, post-etch cleans, post-CMP cleans and deposition, and high-purity liquid materials packaging solutions. Microelectronics products represent the largest portion of ATMI’s business and development activities. The principal drivers for this market are technical performance, yield improvement, time to market, cost, utilization of capital, and risk reduction. The success of an electronic component or device is determined by the increased functionality it can deliver at an acceptable cost.
	The life sciences industry has been using disposable components like filters, connectors, and disposable storage bags for several years; however, as customers migrate toward processes which integrate disposable components into disposable systems, we see growing opportunities. The LifeSciences business unit sells products that address an increasing number of critical process steps for biopharmaceutical manufacturing of vaccines, monoclonal antibodies, and cell therapy applications, including disposable mixers and bioreactors, both considered growth opportunities for ATMI. This unit includes our Newform™ products and Integrity® suite of single-use technology mixers, bioreactors and bioprocess vessels.
	The All Other category includes corporate expenses, and, revenues and expenses associated with early stage new market opportunities such as our eVOLV™ and BrightBlack® technologies.
	The Company evaluates performance and allocates resources based on profit or loss from operations. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.
		Revenue (1)
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Microelectronics	$	87,828		$	98,477		$	265,353		$	276,460
	LifeSciences	12,307			10,388			35,532			30,651
	All Other	97			(18		)	762			209
	Total Consolidated	$	100,232		$	108,847		$	301,647		$	307,320
	(1)	Intersegment sales for the three and nine month periods ended September 30, 2013 and 2012 were not material.
		Operating income (loss)
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Microelectronics	$	25,301		$	34,388		$	77,469		$	85,817
	LifeSciences	(909		)	(2,137		)	(3,849		)	(5,367		)
	All Other	(13,345		)	(11,788		)	(39,521		)	(36,904		)
	Total Consolidated	$	11,047		$	20,463		$	34,099		$	43,546

Basis_Of_Presentation_And_Othe1

Basis Of Presentation And Other Information (Policy)	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying consolidated interim financial statements of ATMI, Inc. at September 30, 2013 and for the three and nine months ended September 30, 2013 and 2012, respectively, are unaudited, but in the opinion of management include all adjustments necessary for a fair presentation of the results for the interim periods. The unaudited consolidated interim financial statements included herein should be read in conjunction with the December 31, 2012 audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012. The Company’s quarterly results are subject to fluctuation and, thus, the operating results for any quarter are not necessarily indicative of results to be expected for any future fiscal period.
	The consolidated balance sheet at December 31, 2012 has been derived from the audited financial statements at that date, but does not include all of the financial information and disclosures required by United States Generally Accepted Accounting Principles (“GAAP”) for complete financial statements.

Basis_Of_Presentation_And_Othe2

Basis Of Presentation And Other Information (Tables)	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Computation Of Earnings Per Share	This table shows the computation of basic and diluted earnings per share (in thousands, except per share data):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2013				2012			2013		2012
	Numerator:
	Net income	$	8,448			$	14,425		26,321		29,710
	Denominator:
	Denominator for basic earnings per share - weighted average shares	31,861				31,964			31,937		31,904
	Dilutive effect of employee stock options	162				145			143		178
	Dilutive effect of restricted stock awards and restricted stock units	727				500			647		577
	Denominator for diluted earnings per common share – weighted average shares	32,750				32,609			32,727		32,659
	Earnings per share-basic	$	0.27			$	0.45		$	0.82	$	0.93
	Earnings per share-diluted	$	0.26			$	0.44		$	0.8	$	0.91
Antidilutive Securities Excluded From Computation	This table shows the potential common shares excluded from the calculation of weighted-average shares outstanding because their effect was considered to be antidilutive (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	Antidilutive shares	573			1,085			861		1,117
Components Of Inventories	Inventories include (in thousands):
		September 30,				December 31,
		2013				2012
	Raw materials	$	30,565			$	26,874
	Work in process	3,305				2,064
	Finished goods	68,023				62,003
		101,893				90,941
	Excess and obsolescence reserve	(3,968		)		(3,386		)
	Inventories, net	$	97,925			$	87,555

EquityBased_Compensation_Table

Equity-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule Of Shares Available	This table shows the number of shares approved by stockholders for each plan and the number of shares that remain available for equity awards at September 30, 2013 (in thousands):
		# of Shares	# of Shares
	Stock Plan	Approved	Available
	2010 Stock Plan (1)	3,000	2,206
	Employee Stock Purchase Plan (2)	1,000	230
	Totals	4,000	2,436
	(1)	Exercise prices for ISOs and non-qualified stock options granted under this plan may not be less than 100 percent of the fair market value for the Company’s common stock on the date of grant.
	(2)	Employees may purchase shares at 95 percent of the closing price on the day previous to the last day of each six-month offering period. This plan is not considered to be compensatory.

Fair_Value_Measurements_And_Ma1

Fair Value Measurements And Marketable Securities(Tables)	9 Months Ended
	Sep. 30, 2013
Investments, All Other Investments [Abstract]
Assets And Liabilities Measured At Fair Value On Recurring Basis	This table summarizes the Company’s assets and liabilities measured at fair value on a recurring basis at September 30, 2013 (in thousands):
				Fair Value Measured Using
		Total		Quoted			Significant		Significant
				Prices in			Other		Unobservable
				Active			Observable		Inputs
				Markets for			Inputs		(Level 3)
				Identical			(Level 2)
				Assets
				(Level 1)
	Cash & cash equivalents	$	61,756	61,756
	Available-for-sale marketable securities
	Common stock	$	18,841	$	18,841
	Time deposits	$	22,337	$	22,337
	Corporate debt obligations	$	7,257				$	7,257
	Government debt obligations	$	24,380				$	24,380
	Government sponsored debt obligations	$	3,729				$	3,729
	Foreign currency exchange contract asset	$	1	$	1
	Foreign currency exchange contract liability	$	22	$	22
Schedule Of Marketable Securities	Marketable securities include at September 30, 2013 and December 31, 2012 (in thousands):
		2013							2012
		Cost		Gross			Estimated		Cost			Gross			Estimated
				Unrealized			Fair Value					Unrealized			Fair Value
				Gain (Loss) (3)								Gain (Loss) (3)
	Securities in unrealized gain position:
	Common stock	$	251	$	1,131		$	1,382	$	22,376		$	13,049		$	35,425
	Corporate debt obligations	3,429		6			3,435		4,211			4			4,215
	Government debt obligations (1)	21,489		11			21,500		4,495			14			4,509
	GSE (2) debt obligations	—		—			—		3,501			—			3,501
	U.S. Treasury obligations	—		—			—		4,023			—			4,023
	Subtotal	25,169		1,148			26,317		38,606			13,067			51,673
	Securities in unrealized loss position:
	Common stock	18,748		(1,289		)	17,459		—			—			—
	Corporate debt obligations	3,825		(3		)	3,822		4,844			(7		)	4,837
	Government debt obligations	2,882		(2		)	2,880		—			—			—
	GSE debt obligations	3,730		(1		)	3,729		—			—			—
	U.S. Treasury obligations	—		—			—		8,251			(1		)	8,250
	Subtotal	29,185		(1,295		)	27,890		13,095			(8		)	13,087
	Securities at amortized cost:
	Time deposits	22,337		—			22,337		16,920			—			16,920
	Corporate debt obligations	—		—			—		790			—			790
	Subtotal	22,337		—			22,337		17,710			—			17,710
	Total marketable securities	$	76,691	$	(147	)	$	76,544	$	69,411		$	13,059		$	82,470
	(1)	State and municipal government debt obligations.
	(2)	Government sponsored enterprise.
	(3)	Unrealized gains or losses of less than $500 for each category are reflected as a dash.
Investments Classified by Contractual Maturity Date	The amortized cost and estimated fair value of available-for-sale securities, by contractual maturity, as of September 30, 2013 are shown below (in thousands); expected maturities may differ from contractual maturities because the issuers of the securities may exercise the right to prepay obligations without prepayment penalties.
		Cost		Estimated
				Fair Value
	Due in one year or less	$	49,700	$	49,709
	Due between one and three years	7,992		7,994
		57,692		57,703
	Common stock	18,999		18,841
		$	76,691	$	76,544
Schedule Of Unrealized Loss On Investments	This table shows the Company’s marketable securities that were in an unrealized loss position at September 30, 2013, and also shows the period of time the security had been in an unrealized loss position (in thousands):
		Less Than 12 Months					12 Months or Greater					Total
		Fair Value		Unrealized			Fair Value		Unrealized			Fair Value			Unrealized
				Losses					Losses						Losses
	Common stock	$	17,459	$	(1,289	)	$	—	$	—		$	17,459		$	(1,289	)
	Corporate debt obligations	$	—	$	—		$	3,822	$	(3	)	$	3,822		$	(3	)
	Government debt obligations	2,880		(2		)	—		—			2,880			(2		)
	GSE (1) debt obligations	3,729		(1		)	—		—			3,729			(1		)
	Total (2)	$	24,068	$	(1,292	)	$	3,822	$	(3	)	$	27,890		$	(1,295	)
	(1)	Government sponsored enterprise.
	(2)	As of September 30, 2013, we had 10 securities in an unrealized loss position.

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Components Of Accumulated Other Comprehensive Income	The components of accumulated other comprehensive income are (in thousands):
		Currency			Unrealized			Unrealized			Total
		Translation			Gain (Loss)			Gain (Loss)
		Adjustments			on Available-			on Derivative
					for-Sale			Instruments
					Securities
	Balance at December 31, 2012	$	6,300		$	8,230		$	1,098		$	15,628
	Reclassification adjustment related to marketable securities in net unrealized gain at prior period end, net of $1,140 tax provision (1)	—			(2,002		)	—			(2,002		)
	Change in fair value of available-for-sale securities, net of deferred income tax of $3,650	—			(6,338		)	—			(6,338		)
	Reclassification adjustment related to cash flow hedges at prior period end in a net unrealized loss at prior period end, net of deferred income tax of $334	—			—			(585		)	(585		)
	Change in fair value of cash flow hedges, net of deferred income tax of $511	—			—			896			896
	Cumulative translation adjustment	(185		)	—			—			(185		)
											(8,214		)
	Balance at September 30, 2013	$	6,115		$	(110	)	$	1,409		$	7,414
	(1)	Determined based on the average cost method
Reclassifications out of Accumulated Other Comprehensive Income	The reclassifications out of accumulated other comprehensive income are (in thousands):
	Details about Accumulated Other Comprehensive	Amount Reclassified from			Effect on the Consolidated
	Income Components	Accumulated Other			Statements of Comprehensive Income
		Comprehensive Income
	Realized gains and losses on cash flow hedges
	Foreign exchange contracts	$	1,057		Revenues
		(138		)	Cost of revenues
		919			Total before tax
		(334		)	Estimated tax expense
		$	585		Net of estimated tax
	Realized gains and losses on available-for-sale securities
	Available-for-sale securities	$	3,142		Other income (expense), net
		3,142			Total before tax
		(1,140		)	Estimated tax expense
		$	2,002		Net of estimated tax
	Total reclassifications for the period	$	2,587		Net of estimated tax

Segments_Tables

Segments (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting, Measurement Disclosures [Abstract]
Reconciliation Of Revenue From Segments To Consolidated	The Company evaluates performance and allocates resources based on profit or loss from operations. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.
		Revenue (1)
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Microelectronics	$	87,828		$	98,477		$	265,353		$	276,460
	LifeSciences	12,307			10,388			35,532			30,651
	All Other	97			(18		)	762			209
	Total Consolidated	$	100,232		$	108,847		$	301,647		$	307,320
	(1)	Intersegment sales for the three and nine month periods ended September 30, 2013 and 2012 were not material.
Reconciliation Of Operating Profit (Loss) From Segments To Consolidated
		Operating income (loss)
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Microelectronics	$	25,301		$	34,388		$	77,469		$	85,817
	LifeSciences	(909		)	(2,137		)	(3,849		)	(5,367		)
	All Other	(13,345		)	(11,788		)	(39,521		)	(36,904		)
	Total Consolidated	$	11,047		$	20,463		$	34,099		$	43,546

Basis_Of_Presentation_And_Othe3

Basis Of Presentation And Other Information (Computation Of Earnings Per Share) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Line Items]
Net income	$8,448	$14,425	$26,321	$29,710
Denominator for basic earnings per share - weighted average shares	31,861	31,964	31,937	31,904
Denominator for diluted earnings per common share – weighted average shares	32,750	32,609	32,727	32,659
Earnings per share-basic (in dollars per share)	$0.27	$0.45	$0.82	$0.93
Earnings per share-diluted (in dollars per share)	$0.26	$0.44	$0.80	$0.91
Employee Stock Option [Member]
Earnings Per Share [Line Items]
Dilutive effect of share based compensation (in shares)	162	145	143	178
Restricted Stock [Member]
Earnings Per Share [Line Items]
Dilutive effect of share based compensation (in shares)	727	500	647	577

Basis_Of_Presentation_And_Othe4

Basis Of Presentation And Other Information (Antidilutive Securities Excluded from Computation) (Details)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Antidilutive shares	573	1,085	861	1,117

Basis_Of_Presentation_And_Othe5

Basis Of Presentation And Other Information (Components Of Inventories) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$30,565	$26,874
Work in process	3,305	2,064
Finished goods	68,023	62,003
Inventories, gross	101,893	90,941
Excess and obsolescence reserve	-3,968	-3,386
Inventories, net	$97,925	$87,555

Basis_Of_Presentation_And_Othe6

Basis Of Presentation And Other Information (Non-Marketable Equity Securities, Narrative) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Non-marketable equity securities, carrying value	$16.40	$8.10
Cost basis investments	7.1	5.4
Non-marketable equity securities, accounted for using equity method accounting	$9.30	$2.70

Basis_Of_Presentation_And_Othe7

Basis Of Presentation And Other Information (Income Taxes, Narrative) (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Income Tax Contingency [Line Items]
Undistributed foreign earnings	$100.40	$100.40
Effective income tax rate	26.60%	28.50%
U.S. federal statutory income tax rate		35.00%
Tax settlements		1.2
Tax benefits related to The American Taxpayer Relief Act of 2012		1.1
Net benefit for reversals of reserves		2.2
Tax provision from share-based compensation expense		0.2
Effective income tax rate, if certain tax benefits and credits were recognized	25.60%	24.50%
Unrecognized tax benefits that would impact effective tax rate if recognized	2.6	2.6
Unrecognized tax benefits related to reaquired rights	27	27
Unrecognized tax benefits decreases resulting from settlements with Internal Revenue Service		8.2
Unrecognized tax benefits decreases resulting from interest associated with settlements with Internal Revenue Service		0.2
Net accrued interest on tax reserves	0.5	0.5
Deferred Taxes [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits that would impact effective tax rate if recognized	0.2	0.2
Other Current Liabilities [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits that would impact effective tax rate if recognized	0.2	0.2
Other Noncurrent Liabilities [Member]
Income Tax Contingency [Line Items]
Unrecognized tax benefits that would impact effective tax rate if recognized	$2.20	$2.20

Basis_Of_Presentation_And_Othe8

Basis Of Presentation And Other Information (Variable Interest Entity, Narrative) (Details) (USD $)	Sep. 30, 2013
In Millions, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable interest entity, carrying amount	$3.90
Variable interest entity, maximum loss exposure	$3.90

Basis_Of_Presentation_And_Othe9

Basis Of Presentation And Other Information (Severance Expense, Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Severance expense	$0.80	$1.80
Severance payments			$1.70

EquityBased_Compensation_Narra

Equity-Based Compensation (Narrative) (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued under employee stock option plans	207,288	258,446
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted in period	324,315	321,965

EquityBased_Compensation_Sched

Equity-Based Compensation (Schedule Of Shares Available) (Details)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
# of Shares Approved	4,000
# of Shares Available	2,436
Exercise price as a percentage of common stock fair market value	100.00%
Employee purchase rate, percentage of closing price	95.00%
2010 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
# of Shares Approved	3,000	[1]
# of Shares Available	2,206	[1]
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
# of Shares Approved	1,000	[2]
# of Shares Available	230	[2]
[1]	Exercise prices for ISOs and non-qualified stock options granted under this plan may not be less than 100 percent of the fair market value for the Company’s common stock on the date of grant.
[2]	Employees may purchase shares at 95 percent of the closing price on the day previous to the last day of each six-month offering period. This plan is not considered to be compensatory.

Fair_Value_Measurements_And_Ma2

Fair Value Measurements And Marketable Securities (Narrative) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Investments, All Other Investments [Abstract]
Fair value inputs, discount rate	5.50%
Contingent payments tied to future revenue performance, range of possible outcomes, low	$0
Contingent payments tied to future revenue performance, range of possible outcomes, high	23,300,000
Fair value of contingent payments	4,900,000
Fair value of contingent payments, increase (decrease) in estimated future payments	$300,000

Fair_Value_Measurements_And_Ma3

Fair Value Measurements And Marketable Securities (Assets And Liabilities Measured At Fair Value On Recurring Basis) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash & cash equivalents	$61,756
Available-for-sale marketable securities	76,544	82,470
Foreign currency exchange contract asset	1
Foreign currency exchange contract liability	22
Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities	18,841
Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities	22,337
Corporate Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities	7,257
Government Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities	24,380
Government Sponsored Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities	3,729
Fair Value Measured Using Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash & cash equivalents	61,756
Foreign currency exchange contract asset	1
Foreign currency exchange contract liability	22
Fair Value Measured Using Quoted Prices In Active Markets For Identical Assets (Level 1) [Member] | Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities	18,841
Fair Value Measured Using Quoted Prices In Active Markets For Identical Assets (Level 1) [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities	22,337
Fair Value Measured Using Quoted Prices In Active Markets For Identical Assets (Level 1) [Member] | Corporate Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities
Fair Value Measured Using Quoted Prices In Active Markets For Identical Assets (Level 1) [Member] | Government Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities
Fair Value Measured Using Quoted Prices In Active Markets For Identical Assets (Level 1) [Member] | Government Sponsored Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities
Fair Value Measured Using Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash & cash equivalents
Foreign currency exchange contract asset
Foreign currency exchange contract liability
Fair Value Measured Using Significant Other Observable Inputs (Level 2) [Member] | Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities
Fair Value Measured Using Significant Other Observable Inputs (Level 2) [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities
Fair Value Measured Using Significant Other Observable Inputs (Level 2) [Member] | Corporate Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities	7,257
Fair Value Measured Using Significant Other Observable Inputs (Level 2) [Member] | Government Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities	24,380
Fair Value Measured Using Significant Other Observable Inputs (Level 2) [Member] | Government Sponsored Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities	3,729
Fair Value Measured Using Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash & cash equivalents
Foreign currency exchange contract asset
Foreign currency exchange contract liability
Fair Value Measured Using Significant Unobservable Inputs (Level 3) [Member] | Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities
Fair Value Measured Using Significant Unobservable Inputs (Level 3) [Member] | Time Deposits [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities
Fair Value Measured Using Significant Unobservable Inputs (Level 3) [Member] | Corporate Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities
Fair Value Measured Using Significant Unobservable Inputs (Level 3) [Member] | Government Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities
Fair Value Measured Using Significant Unobservable Inputs (Level 3) [Member] | Government Sponsored Debt Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale marketable securities

Fair_Value_Measurements_And_Ma4

Fair Value Measurements And Marketable Securities (Schedule Of Marketable Securities) (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Cost	$76,691		$69,411
Gross Unrealized Gain (Loss)	-147		13,059	[1]
Estimated Fair Value	76,544		82,470
Common Stock [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	18,999
Estimated Fair Value	18,841
Securities In Unrealized Gain Position [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	25,169		38,606
Gross Unrealized Gain (Loss)	1,148		13,067	[1]
Estimated Fair Value	26,317		51,673
Securities In Unrealized Gain Position [Member] | Common Stock [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	251		22,376
Gross Unrealized Gain (Loss)	1,131		13,049	[1]
Estimated Fair Value	1,382		35,425
Securities In Unrealized Gain Position [Member] | Corporate Debt Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	3,429		4,211
Gross Unrealized Gain (Loss)	6		4	[1]
Estimated Fair Value	3,435		4,215
Securities In Unrealized Gain Position [Member] | Government Debt Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	21,489	[2]	4,495	[2]
Gross Unrealized Gain (Loss)	11	[2]	14	[1],[2]
Estimated Fair Value	21,500	[2]	4,509	[2]
Securities In Unrealized Gain Position [Member] | Government Sponsored Debt Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	0	[3]	3,501	[3]
Gross Unrealized Gain (Loss)	0	[3]	0	[1],[3]
Estimated Fair Value	0	[3]	3,501	[3]
Securities In Unrealized Gain Position [Member] | U.S. Treasury Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	0		4,023
Gross Unrealized Gain (Loss)	0		0	[1]
Estimated Fair Value	0		4,023
Securities In Unrealized Loss Position [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	29,185		13,095
Gross Unrealized Gain (Loss)	-1,295		-8	[1]
Estimated Fair Value	27,890		13,087
Securities In Unrealized Loss Position [Member] | Common Stock [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	18,748		0
Gross Unrealized Gain (Loss)	-1,289		0	[1]
Estimated Fair Value	17,459		0
Securities In Unrealized Loss Position [Member] | Corporate Debt Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	3,825		4,844
Gross Unrealized Gain (Loss)	-3		-7	[1]
Estimated Fair Value	3,822		4,837
Securities In Unrealized Loss Position [Member] | Government Debt Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	2,882		0
Gross Unrealized Gain (Loss)	-2		0	[1]
Estimated Fair Value	2,880		0
Securities In Unrealized Loss Position [Member] | Government Sponsored Debt Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	3,730		0
Gross Unrealized Gain (Loss)	-1		0	[1]
Estimated Fair Value	3,729		0
Securities In Unrealized Loss Position [Member] | U.S. Treasury Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	0		8,251
Gross Unrealized Gain (Loss)	0		-1	[1]
Estimated Fair Value	0		8,250
Securities At Amortized Cost [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	22,337		17,710
Gross Unrealized Gain (Loss)	0		0	[1]
Estimated Fair Value	22,337		17,710
Securities At Amortized Cost [Member] | Time Deposits [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	22,337		16,920
Gross Unrealized Gain (Loss)	0		0	[1]
Estimated Fair Value	22,337		16,920
Securities At Amortized Cost [Member] | Corporate Debt Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	0		790
Gross Unrealized Gain (Loss)	0		0	[1]
Estimated Fair Value	$0		$790
[1]	Unrealized gains or losses of less than $500 for each category are reflected as a dash.
[2]	State and municipal government debt obligations.
[3]	Government sponsored enterprise.

Fair_Value_Measurements_And_Ma5

Fair Value Measurements And Marketable Securities (Investments Classified by Contractual Maturity Date) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Due in one year or less, Cost	$49,700
Due between one and three years, Cost	7,992
Total maturities, Cost	57,692
Available-for-sale securities, Cost	76,691	69,411
Due in one year or less, Estimated Fair Value	49,709
Due between one and three years, Estimated Fair Value	7,994
Total maturities, Estimated Fair Value	57,703
Available-for-sale securities, Estimated Fair Value	76,544	82,470
Common Stock [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost	18,999
Available-for-sale securities, Estimated Fair Value	$18,841

Fair_Value_Measurements_And_Ma6

Fair Value Measurements And Marketable Securities (Schedule Of Unrealized Loss On Investments) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
	security
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Fair Value	$24,068	[1]
Less Than 12 Months, Unrealized Losses	-1,292	[1]
12 Months or Greater, Fair Value	3,822	[1]
12 Months or Greater, Unrealized Losses	-3	[1]
Total Fair Value	27,890	[1]
Total Unrealized Losses	-1,295	[1]
Securities in an unrealized loss position	10
Common Stock [Member]
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Fair Value	17,459
Less Than 12 Months, Unrealized Losses	-1,289
12 Months or Greater, Fair Value	0
12 Months or Greater, Unrealized Losses	0
Total Fair Value	17,459
Total Unrealized Losses	-1,289
Corporate Debt Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Fair Value	0
Less Than 12 Months, Unrealized Losses	0
12 Months or Greater, Fair Value	3,822
12 Months or Greater, Unrealized Losses	-3
Total Fair Value	3,822
Total Unrealized Losses	-3
Government Debt Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Fair Value	2,880
Less Than 12 Months, Unrealized Losses	-2
12 Months or Greater, Fair Value	0
12 Months or Greater, Unrealized Losses	0
Total Fair Value	2,880
Total Unrealized Losses	-2
Government Sponsored Debt Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Fair Value	3,729	[2]
Less Than 12 Months, Unrealized Losses	-1	[2]
12 Months or Greater, Fair Value	0	[2]
12 Months or Greater, Unrealized Losses	0	[2]
Total Fair Value	3,729	[2]
Total Unrealized Losses	($1)	[2]
[1]	As of September 30, 2013, we had 10 securities in an unrealized loss position. We have evaluated the near-term prospects of the investments in relation to the severity and duration of the decline in fair value and based on that evaluation we have concluded that we have the ability and intent to hold these investments until the recovery of fair value.
[2]	Government sponsored enterprise.

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Components Of Accumulated Other Comprehensive Income) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Accumulated Other Comprehensive Income [Roll Forward]
Currency Translation Adjustments, Begining Balance	$6,300
Cumulative translation adjustment	-185
Currency Translation Adjustment, Ending Balance	6,115
Unrealized Gain (Loss) on Available-for-Sale Securities, Begining Balance	8,230
Reclassification adjustment related to marketable securities in net unrealized gain at prior period end, net of $685 tax provision	-2,002	[1]
Change in fair value of available-for-sale securities, net of deferred income tax of $3,650	-6,338
Unrealized Gain (Loss) on Available-for-Sale Securities, Ending Balance	-110
Unrealized Gain (Loss) On Derivative Instruments, Beginning Balance	1,098
Reclassification adjustment related to cash flow hedges at prior period end in a net unrealized loss at prior period end, net of deferred income tax of $334	-585
Change in fair value of cash flow hedges, net of deferred income tax of $511	896
Unrealized Gain (Loss) On Derivative Instruments, Ending Balance	1,409
Begining Balance	15,628
Other Comprehensive loss	-8,214
Ending Balance	7,414
Reclassification adjustment related to marketable securities in net unrealized gain position at prior period end, tax	1,140
Change in fair value of available-for-sale securities, tax	3,650
Reclassification adjustment related to derivative financial instruments, tax	334
Change in fair value of derivative financial instruments, tax	$511
[1]	Determined based on the average cost method

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income (Reclassifications Out Of Accumulated Other Comprehensive Income) (Details) (USD $)	3 Months Ended				9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Revenues	$100,232	[1]	$108,847	[1]	$301,647	[1]	$307,320	[1]
Other income, net	218		254		1,838		-509
Cost of revenues	-53,978		-54,404		-160,049		-155,221
Total before tax	11,505		21,010		36,833		43,960
Estimated tax expense	-3,057		-6,585		-10,512		-14,250
Net of estimated tax	8,448		14,425		26,321		29,710
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Net of estimated tax					2,587
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Revenues					1,057
Cost of revenues					-138
Total before tax					919
Estimated tax expense					-334
Net of estimated tax					585
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Unrealized Investment Gain (Loss) [Member]
Reclassification Adjustment Out Of Accumulated Other Comprehensive Income [Line Items]
Other income, net					3,142
Total before tax					3,142
Estimated tax expense					-1,140
Net of estimated tax					$2,002
[1]	ntersegment sales for the three and nine month periods ended September 30, 2013 and 2012 were not material.

Foreign_Currency_Exchange_Cont1

Foreign Currency Exchange Contracts (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Derivative [Line Items]
Accumulated net unrecognized gains (losses) that are expected to be reclassified into earnings during the next twelve months	$1.30		$1.30
Net gain related to changes in the fair value of foreign currency exchange contracts	0.5	0.1	0.1	0.6
Increase in the fair value of cash flow hedges	0.6		0.3	0.2
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Notional Amount	21.2		21.2
Not Designated as Hedging Instrument [Member] | Euro Member Countries, Euro
Derivative [Line Items]
Derivative, Notional Amount	8.3		8.3
Not Designated as Hedging Instrument [Member] | Taiwan, New Dollars
Derivative [Line Items]
Derivative, Notional Amount	1.4		1.4
Not Designated as Hedging Instrument [Member] | China, Yuan Renminbi
Derivative [Line Items]
Derivative, Notional Amount	1.2		1.2
Not Designated as Hedging Instrument [Member] | Japan, Yen
Derivative [Line Items]
Derivative, Notional Amount	10.3		10.3
Cash Flow Hedging [Member] | Japan, Yen
Derivative [Line Items]
Derivative, Notional Amount	$15.60		$15.60

Commitments_And_Contingencies_

Commitments And Contingencies (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]
Fair value of contingent payments	$4,900,000
Contingent payments tied to future revenue performance, range of possible outcomes, low	0
Contingent payments tied to future revenue performance, range of possible outcomes, high	23,300,000
Commitment to purchase raw material	16,000,000
Time period to purchase raw material	P2Y
Purchases Made Under Long Term Purchase Commitment	7,000,000
Remaining commitment to purchase raw material	$9,000,000

Segments_Narrative_Details

Segments (Narrative) (Details)	9 Months Ended
	Sep. 30, 2013
	segment
Segment Reporting [Abstract]
Number of Operating Segments	2

Segments_Reconciliation_of_Rev

Segments (Reconciliation of Revenue from Segments to Consolidated) (Details) (USD $)	3 Months Ended				9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenues	$100,232	[1]	$108,847	[1]	$301,647	[1]	$307,320	[1]
Microelectronics [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenues	87,828	[1]	98,477	[1]	265,353	[1]	276,460	[1]
LifeSciences [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenues	12,307	[1]	10,388	[1]	35,532	[1]	30,651	[1]
All Other [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenues	$97	[1]	($18)	[1]	$762	[1]	$209	[1]
[1]	ntersegment sales for the three and nine month periods ended September 30, 2013 and 2012 were not material.

Segments_Reconciliation_Of_Ope

Segments (Reconciliation Of Operating Profit (Loss) From Segments To Consolidated) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating income	$11,047	$20,463	$34,099	$43,546
Microelectronics [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating income	25,301	34,388	77,469	85,817
LifeSciences [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating income	-909	-2,137	-3,849	-5,367
All Other [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Operating income	($13,345)	($11,788)	($39,521)	($36,904)